Commentary on "Meta-analysis of six-month memantine trials in Alzheimer's disease." Memantine has negligible benefits in mild to moderate Alzheimer's disease.
Knopman
David S
DS
Mayo Alzheimer Disease Research Center and the Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA. knopman@mayo.edu